Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies Burger, J. A., O'Brien, S., Fowler, N., Advani, R., Sharman, J., Furman, R. R., Izumi, R., Buggy, J., Loury, D., Hamdy, A., Byrd, J. C., Blum, K. A. AMER SOC HEMATOLOGY. 2010: 32

View details for Web of Science ID 000289662200058